Tetra Bio-Pharma Inc. TBP.TO
Day range unavailable
52-week range unavailable
- Market cap
- 10.58M
- Shares out
- 423.36M
- Beta
- 2.20
Key statistics
- Enterprise value
- 11.76M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -3.52M
- Total cash
- 483.20K
- Total debt
- 1.66M
- Return on equity
- -315.85%
- Short % of float
- 0.00%
- 50-day average
- 0.025
- 200-day average
- 0.026125
Next earnings
Consensus EPS estimate 0.00.
About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. has an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug. The company is headquartered in Orléans, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- tetrabiopharma.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on TBP.TO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Auld, Leslie | Senior Officer of Issuer | Opening Balance-Initial SEDI Report | May 29, 2022 | 0 |
| Kim, John | Director of Issuer | Acquisition or disposition under a prospectus exemption | Dec 20, 2021 | 496,000 |